AlphAIAlphAI — Financial news for AI agents
rttnews.comSEP 102 min read$BNR

Burning Rock Q2 Revenue Falls 9%; In-Hospital Business Posts Growth

Burning Rock Biotech (BNR) reported Q2 2026 revenue of RMB134.8M, down 9% YoY. In-hospital business revenue grew to RMB67.1M, while central lab and pharma R&D services declined. Gross profit was RMB97.8M, with a gross margin of 72.6%. Net loss was RMB18.4M. The company expects regulatory progress and new product approvals to drive long-term growth. BNR stock is currently at $12.17, up 1.49%.

Original reporting
rttnews.com
Published Sep 10, 2026, 5:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 6:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$BNR
Bearish
medium confidence
Mentioned
$BNR
Relevance
6/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$BNRBearishMed
01

Why it matters

The earnings miss may trigger short‑term selling, but ongoing regulatory submissions and a shift to higher‑margin in‑hospital testing could mitigate longer‑term downside.

02

Market read

First‑time Q2 earnings disclosure for a small‑cap biotech; relevant for traders tracking Chinese biotech earnings and regulatory pipelines.

03

What to watch

Cash balance of RMB419 million provides runway; in‑hospital growth may accelerate later in the year.

Relevance 6/10Novelty 8/10Timing: post‑market today

Background

Burning Rock Biotech Limited (BNR) released its Q2 2026 earnings, showing a revenue decline and higher net loss while reporting progress on product regulatory reviews.

Company-level read

Ticker impact

$BNRBearishMedium confidence
Context

Q2 2026 revenue fell 9% YoY to RMB134.8 million and net loss widened to RMB18.4 million.

Expected impact

Potential downside of 5‑8% over the next few days.

Evidence & confidence

Revenue decline and widening loss signal slower growth; however, in‑hospital revenue growth and regulatory progress could limit the drop.

Market effects

Sector

Highlights pressure on Chinese precision‑oncology and NGS service providers.

Regional

May weigh on other China‑listed biotech stocks reporting Q2 results.

Global

Limited; primarily a regional biotech story.

Counterpoint

What could challenge this read

Regulatory approvals in the pipeline could offset the revenue dip and support a rebound.

Key entities

  • company
    Burning Rock Biotech Limited

    Precision oncology firm listed on NASDAQ under ticker BNR.

Read at source← All news

Related articles

SEP 10
$BNRMed

Burning Rock Biotech Ltd (BNR): Financial results for Q2 2026

Burning Rock Biotech Ltd (BNR) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Burning Rock Reports Second Quarter 2026 Financial Results GUANGZHOU, China, September 10, 2026—Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next-generation sequencing (NGS) technology in the fie

SEC EDGAR 6-K2 min
SEP 21
$PLBLMed

Polibeli Group Ltd (PLBL): Financial results for H1 2026

Polibeli Group Ltd (PLBL) furnished an SEC Form 6-K — earnings release. Polibeli Group Ltd Announces Unaudited Financial Results for the six months ended June 30, 2026 On September 21, 2026, Polibeli Group Ltd (the “Company”) announced its unaudited financial results for the six months ended June 30, 2026. Business and Strategic Update ● As of the da

SEC EDGAR 6-K2 min
SEP 21
$VICRHighAI 8/10

Why is Vicor stock surging today?

Vicor Corporation's stock rose 12.3% after hours after raising its Q3 2026 revenue growth guidance from nearly 10% to over 20%, driven by royalties from its VPD licensing program. Four major companies have licensed the technology, and the CEO noted potential supply disruptions for unlicensed suppliers. The company also recently authorized a $150M share buyback and acquired properties for AI-driven demand. The Nasdaq closed at a record high, led by AI stocks, but broader indices were unchanged.

investing.com2 min
SEP 21
$OPTULow

Optimum Communications, Inc. (OPTU): Results of Operations and Financial Condition

Optimum Communications, Inc. (OPTU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Item 2.02 Results of Operations and Financial Condition. The information appearing below under Item 4.02 regarding certain previously reported financial information of Optimum Communications, Inc. (the "Company") for the fiscal year ended December 31, 2025, and the fiscal quarter

SEC EDGAR 8-K2 min
SEP 21
$ABVXMedAI 8/10

EQS-News: ABIVAX: Abivax Presents Business Updates and First Half 2026 Financial Results

Abivax reported H1 2026 financials with €402.4M in cash and €767.1M from a July offering, extending runway to Q4 2029. Leadership changes include Chris Rabbat as CMO and Tim Kelly as CTO. The company repurchased royalty certificates for €76.5M, reducing debt. R&D expenses rose 38.5% YoY to €107.9M, driven by clinical trial progress and new indications for obefazimod.

finanznachrichten.de3 min